Trump’s push to onshore pharma manufacturing clouded by ‘lack of clarity’
A degree of uncertainty reigns over the implementation of regulations imposed by US President Donald Trump that aim to bolster …
Post
-
-
Antares Therapeutics gains $177m for cancer medicines development
Antares Therapeutics has secured $177m in a Series A financing round for the development of precision medicines to treat cancer …
-
Outlook’s wet AMD treatment accepted by SMC for NHS Scotland
The Scottish Medicines Consortium (SMC) has accepted Outlook Therapeutics’ Lytenava (bevacizumab gamma) for the treatment of wet age-related macular degeneration (wet …
-
Odyssey bails on public listing as US IPO landscape stutters
Odyssey Therapeutics is unlikely to join the 2025 class of biotechs hitting the stock exchanges after the company withdrew its …
-
Mosanna Therapeutics gains $80m to advance OSA nasal spray
Mosanna Therapeutics has secured $80m in a Series A funding round to advance a new nighttime nasal spray for obstructive …
-
RFK Jr axes vaccine advisory committee members
The US department of Health and Human Services (HHS) has culled the 17 Biden-appointed members on the Advisory Committee for …
-
MSD receives FDA approval for Enflonsia to prevent RSV
MSD has received US Food and Drug Administration (FDA) approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) lower …
-
EC approves Alnylam’s vutrisiran for ATTR-CM treatment
The European Commission (EC) has approved Alnylam Pharmaceuticals' Amvuttra (vutrisiran) to treat wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in adults. Amvuttra …
-
FDA approves YolTech’s YOLT-101 for familial hypercholesterolemia
YolTech Therapeutics has received the US Food and Drug Administration (FDA) approval for its investigational new drug (IND) application for …
-
Podcast: AI and Supervised Machine Learning in Clinical Trials – Part 2
In episode two of The Zelta Podcast, we continue our conversation about AI and supervised machine learning in clinical trials …
-
Aytu BioPharma to commercialise Exxua for MDD in the US
Aytu BioPharma has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua (gepirone) extended-release tablets, a new antidepressant, to …
-
American Society of Clinical Oncology (ASCO) Annual Meeting 2025
The American Society of Clinical Oncology (ASCO) Annual Meeting 2025, held from 30 May to 3 June, in Chicago, Illinois, …
-
The European Market Access Lag: 2021–2024
In this article, GlobalData investigates key reimbursement trends that reflect the current delays to patient access across the European region. …
-
EC approves AstraZeneca’s acalabrutinib combo for CLL
The European Commission (EC) has approved a fixed-duration regimen of AstraZeneca's Bruton’s tyrosine kinase (BTK) selective inhibitor, Calquence (acalabrutinib) plus …
-
SCHOTT Pharma invests in RTU cartridge capacity expansion
Drug containment and delivery solutions provider SCHOTT Pharma has announced an investment of more than €100m ($114m) to expand its …
